New Delhi: Home-grown COVID-19 vaccine Covaxin has shown to develop long-term antibody and T-cell memory responses 3 months after the shot in Phase-1 trials.
Bharat Biotech said the safety outcome in Phase-2 trial was found to be tolerable and it is expected that the antibodies produced will last for 6 to 12 months.
Memory T cells are antigen-specific T cells that stay in the body for a long term after an infection is eliminated. No serious adverse reaction was observed, the company said in a research paper.
Covaxin, now in Phase-3 trials, was tried on 380 healthy children and adults during the Phase-2 trials. As many as 13,000 volunteers have been recruited for Phase III trials and a total of 26,000 participants across multiple sites will be needed for the trials. AIIMS Delhi is recruiting more volunteers to join the trials.
Also Read: Vaccine To Fight New Coronavirus Strain Can Be Made In 6 Weeks If Required: BioNTech
Bargarh: A new artist will be selected to play the mythological character King Kansa during…
Mumbai: Suhana Khan will be making her Bollywood debut with ‘King’ along with her superstar…
New Delhi: After Diljit Dosanjh called out the double standards of Telangana government for banning…
New Delhi: Recent actions and counter-actions in the Russia-Ukraine conflict have pushed the world to the…
Balangir: Three persons were arrested and fake IPS officers’ uniforms along with fake identity cards…
Mumbai: Abhishek Bachchan’s highly-anticipated film ‘I Want To Talk’ released in theatres on Friday, and the…
New Delhi: Accused of giving cash to secure votes ahead of election day in Maharashtra,…
Bhubaneswar: Chief Minister Mohan Charan Majhi attended the ‘Odisha State Day Celebrations’ at the 43rd…